An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression.

ABSTRACT:

Background

Vilazodone, a novel selective serotonin reuptake inhibitor and 5-HT1A partial agonist, was approved in 2011 for treatment for major depression. We aimed to compare the efficacy and safety of vilazodone versus escitalopram in patients with major depression at 4 weeks.

Methods

Participants (n = 52) were adult major depressive disorder outpatients who were randomized to receive either oral escitalopram (modal endpoint dose 20 mg/day; n = 26) or oral vilazodone (modal endpoint dose 40 mg/day; n = 26). Rater-blinded assessments of depression scores (primary outcome) and clinical severity of illness (secondary outcome) were obtained at baseline, 2 weeks, and 4 weeks. Adverse effects such as weight gain, sexual dysfunction, and diarrhea were recorded

SUBMITTER: Kumar PNS 

PROVIDER: S-EPMC9896102 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature